Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 plus Nivolumab in MSS Refractory Metastatic Colorectal Cancer
NCT02860546Phase 2Completed
- Sponsor
- Taiho Oncology
- Start
- Aug 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trifluridine + tipiracil, nivolumab in colorectal cancer (CRC), sponsored by Taiho Oncology. Started Aug 2016; status: completed.
02
Drugs
trifluridine + tipiracilnivolumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02860546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02860546.